Top

Journal of Translational Medicine

Published in:

Open Access 01-12-2022 | Stroke | Research

Diabetes, hypertension, and cardiovascular disease development

Authors: Fu-Shun Yen, James Cheng-Chung Wei, Lu-Ting Chiu, Chih-Cheng Hsu, Chii-Min Hwu

Published in: Journal of Translational Medicine | Issue 1/2022

Abstract

Background

We aimed to compare cardiovascular risks among participants with T2DM with and without subsequent HTN and participants with HTN with and without subsequent T2DM.

Methods

From January 1, 2000, to December 31, 2018, we identified 16,236 matched pairs of T2DM participants with and without HTN (T2DM cohorts), 53,509 pairs of HTN participants with and without T2DM (HTN cohorts), and 21,158 pairs of comorbid HTN and T2DM participants with T2DM history or HTN history (comorbid cohorts) from Taiwan’s National Health Insurance Research Database. Cox proportional-hazard models were used to calculate the risk of cardiovascular disease.

Results

The mean follow-up time of this study was 6.75 years. Mean incident rates of coronary artery disease for T2DM cohorts, HTN cohorts, and comorbid cohorts were 16.80, 23.18, and 31.53 per 1000 person-years, respectively. The adjusted hazard ratios (HRs) (95% confidence intervals [95% CIs]) for incident coronary artery disease, stroke, and heart failure in T2DM participants with versus without HTN were 2.22 (2.07–2.37), 1.19 (1.16–1.23), and 0.92 (0.82–1.02), respectively; the adjusted HRs for HTN participants with versus without T2DM were 1.69 (1.55–1.84), 1.25 (1.21–1.30), and 0.98 (0.93–1.05), respectively; the adjusted HRs for comorbid T2DM and HTN participants with previous T2DM versus previous HTN were 2.78 (2.37–3.27), 1.20 (1.13–1.28), and 0.95 (0.88–1.03), respectively.

Conclusions

This nationwide cohort study demonstrated that both T2DM with subsequent HTN and HTN with subsequent diabetes were associated with higher cardiovascular disease risks.

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–22. doi:https://doi.org/10.1016/s0140-6736(20)30925-9.

GBD 2019. Institute for health metrics and evaluation, global health data exchange, Global Burden of Disease Study 2019 (GBD 2019) data resources, GBD results tool, terms and conditions. 2019. http://ghdx.healthdata.org/gbd-results-tool. Accessed 24 Jan 2021.

Chan JCN, Lim LL, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, et al. The Lancet commission on diabetes: using data to transform diabetes care and patient lives. Lancet. 2021;396:2019–82. https://doi.org/10.1016/s0140-6736(20)32374-6.CrossRefPubMed

Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133:2459–502. https://doi.org/10.1161/CIRCULATIONAHA.116.022194.CrossRefPubMedPubMedCentral

Luo D, Cheng Y, Zhang H, Ba M, Chen P, Li H, et al. Association between high blood pressure and long term cardiovascular events in young adults: systematic review and meta-analysis. BMJ. 2020;370: m3222. https://doi.org/10.1136/bmj.m3222.CrossRefPubMedPubMedCentral

Brownrigg JR, Hughes CO, Burleigh D, Karthikesalingam A, Patterson BO, Holt PJ, et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol. 2016;4:588–97. https://doi.org/10.1016/S2213-8587(16)30057-2.CrossRefPubMed

Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006;49:1761–9. https://doi.org/10.1007/s00125-006-0297-1.CrossRefPubMed

Air EL, Kissela BM. Diabetes, the metabolic syndrome, and ischemic stroke: epidemiology and possible mechanisms. Diabetes Care. 2007;30:3131–40. https://doi.org/10.2337/dc06-1537.CrossRefPubMed

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338: b1665. https://doi.org/10.1136/bmj.b1665.CrossRefPubMedPubMedCentral

10.

SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16. https://doi.org/10.1056/NEJMoa1511939.CrossRef

11.

Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288–98. https://doi.org/10.1007/s00125-009-1470-0.CrossRefPubMed

12.

Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603–15. https://doi.org/10.1001/jama.2014.18574.CrossRefPubMed

13.

Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–72. https://doi.org/10.1016/S0140-6736(09)60697-8.CrossRefPubMed

14.

Cheng TM. Taiwan’s new national health insurance program: genesis and experience so far. Health Aff (Millwood). 2003;22:61–76. https://doi.org/10.1377/hlthaff.22.3.61.CrossRef

15.

Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc. 2005;104:157–63.PubMed

16.

Sung SF, Hsieh CY, Lin HJ, Chen YW, Yang YHK, Li CY. Validation of algorithms to identify stroke risk factors in patients with acute ischemic stroke, transient ischemic attack, or intracerebral hemorrhage in an administrative claims database. Int J Cardiol. 2016;215:277–82. https://doi.org/10.1016/j.ijcard.2016.04.069.CrossRefPubMed

17.

Meduru P, Helmer D, Rajan M, Tseng CL, Pogach L, Sambamoorthi U. Chronic illness with complexity: implications for performance measurement of optimal glycemic control. J Gen Intern Med. 2007;22:408–18. https://doi.org/10.1007/s11606-007-0310-5.CrossRefPubMedPubMedCentral

18.

Young BA, Lin E, Von Korff M, Simon G, Ciechanowski P, Ludman EJ, et al. Diabetes complications severity index and risk of mortality, hospitalization, and health care utilization. Am J Manag Care. 2008;14:15–23.PubMedPubMedCentral

19.

Cheng CL, Lee CH, Chen PS, Li Y, Lin SJ, Yang YHK. Validation of acute myocardial infarction cases in the National Health Insurance Research Database in Taiwan. J Epidemiol. 2014;24:500–7. https://doi.org/10.2188/jea.JE20140076.CrossRefPubMedPubMedCentral

20.

Lin YS, Chen TH, Chi CC, Lin MS, Tung TH, Liu CH, et al. Different implications of heart failure, ischemic stroke, and mortality between non-valvular atrial fibrillation and atrial flutter-a view from a national cohort study. J Am Heart Assoc. 2017;6: e006406. https://doi.org/10.1161/JAHA.117.006406.CrossRefPubMedPubMedCentral

21.

D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–81. https://doi.org/10.1002/(SICI)1097-0258(19981015)17:19%3C2265::AID-SIM918%3E3.0.CO;2-B.CrossRefPubMed

22.

Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370:1514–23. https://doi.org/10.1056/NEJMoa1310799.CrossRefPubMed

23.

Lee CH, Wu YL, Kuo JF, Chen JF, Chin MC, Hung YJ. Prevalence of diabetic macrovascular complications and related factors from 2005 to 2014 in Taiwan: a nationwide survey. J Formos Med Assoc. 2019;118:S96-102. https://doi.org/10.1002/(SICI)1097-0258(19981015)17:19%3C2265::AID-SIM918%3E3.0.CO;2-B.CrossRefPubMed

24.

Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434–44. https://doi.org/10.1056/NEJMoa1310799.CrossRef

25.

Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;21:412–9. https://doi.org/10.1136/bmj.321.7258.412.CrossRef

26.

Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2013;17:20–33. https://doi.org/10.1016/j.cmet.2012.11.012.CrossRefPubMedPubMedCentral

27.

Williams B. Vascular ageing and interventions: lessons and learnings. Ther Adv Cardiovasc Dis. 2016;10:126–32. https://doi.org/10.1177/1753944716642681.CrossRefPubMedPubMedCentral

28.

Picariello C, Lazzeri C, Attanà P, Chiostri M, Gensini GF, Valente S. The impact of hypertension on patients with acute coronary syndromes. Int J Hypertens. 2011;2011: 563657. https://doi.org/10.4061/2011/563657.CrossRefPubMedPubMedCentral

29.

Carey RM, Muntner P, Bosworth HB, Whelton PK. Prevention and control of hypertension: JACC health promotion series. J Am Coll Cardiol. 2018;72:1278–93. https://doi.org/10.1016/j.jacc.2018.07.008.CrossRefPubMedPubMedCentral

Title: Diabetes, hypertension, and cardiovascular disease development
Authors: Fu-Shun Yen
James Cheng-Chung Wei
Lu-Ting Chiu
Chih-Cheng Hsu
Chii-Min Hwu
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Stroke
Heart Failure
Arterial Diseases
Hypertension
Diabetes
Hypertension
Published in: Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-021-03217-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Clinical efficiency of simultaneous CNV-seq and whole-exome sequencing for testing fetal structural anomalies

SAMHD1 silencing cooperates with radiotherapy to enhance anti-tumor immunity through IFI16-STING pathway in lung adenocarcinoma

Glutamine deficiency promotes recurrence and metastasis in colorectal cancer through enhancing epithelial–mesenchymal transition

Continuous high-frequency deep brain stimulation of the anterior insula modulates autism-like behavior in a valproic acid-induced rat model

Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway

DEPTH2: an mRNA-based algorithm to evaluate intratumor heterogeneity without reference to normal controls

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials